Business / Finance

RSS

Clyde Biosciences announces £2 million ‘Series A’ investment

Clyde Biosciences Ltd. has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund.

15 Apr 2015

Atlas Genetics signs diagnostic collaboration to explore new use of io system

Atlas Genetics Ltd, the ultra-rapid 'test and treat' molecular diagnostics company, today announces that it has entered into a collaboration with a major pharmaceutical company to develop a diagnostic test, expanding capabilities beyond infectious diseases.

15 Apr 2015

iCardiac launches industry-first full risk-sharing program for cardiac safety studies

iCardiac Technologies, a market and scientific leader in the conduct of cardiac safety assessments, announced today that it has launched the industry’s first full risk-sharing program for Thorough QT studies. Leveraging its innovative High Precision QT™ methodology for analyzing ECG waveforms, iCardiac’s program guarantees to sponsors that one of two desirable outcomes will be achieved.

14 Apr 2015

BioLight Life Sciences announces first IOPtiMate™ system sale in Hungary

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary.

14 Apr 2015

Clyde Biosciences, a leading drug toxicity testing company, closes Series A investment

Clyde Biosciences Ltd. (Clyde Biosciences) has announced a £2 million ‘Series A’ investment led by Epidarex Capital, a leading international early-stage life science venture capital fund. Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round along with Glasgow University Holdings, Ltd.

14 Apr 2015

EarlySense signs partnership agreement with Mitsui

EarlySense Ltd., the market leader in contact-free monitoring solutions for the hospital and home, announced today it has signed a partnership agreement with Mitsui & Co., Ltd., one of the largest general trading companies in Japan, with revenues of 55.7 Billion USD and net income of 4,099 Million USD for the year ended March 31st, 2014.

14 Apr 2015

Lucideon doubles its wear testing capabilities in the US

Lucideon has invested in a new six station knee wear testing simulator, doubling its capacity to perform knee wear testing for orthopaedic implant manufacturers and taking the total investment in this service to over £1 Million across the group...

From Lucideon 14 Apr 2015

LABORIE completes acquisition of Medical Measurement Systems

LABORIE Medical Technologies has completed its acquisition of Medical Measurement Systems. MMS is headquartered in Enschede, The Netherlands, with a German subsidiary in Bottrop and US operations in Dover, New Hampshire.

13 Apr 2015

Temple/St. Luke's medical students engage Bangor area sixth graders in active learning about health

School to provide an interactive health education and science assembly to interest students in healthy living and disease prevention...

13 Apr 2015

Oxis International resumes trading of common stock on Euronext Paris on April 14, 2015

Oxis International, Inc., a biotechnology company focused on cancer therapy development and commercialization, announced today that trading in its common stock will resume on Euronext Paris on April 14, 2015.

10 Apr 2015

Special concession on PTI training courses for new and growing life science organisations

Following its recent introduction of innovative game-based e-learning modules, Pharmaceutical Training International (PTI) is providing the opportunity to make substantial savings on its full range of training courses to start-ups and SMEs (with fewer than 50 employees), as well as non-profit organisations and government bodies...

From Pharmaceutical Training International 10 Apr 2015

Catamaran acquires Healthcare Solutions for $405 million

Catamaran Corporation, a leading provider of pharmacy benefit management (PBM) services and technology solutions, announced today the completion, effective as of April 8, 2015, of its previously disclosed acquisition of Healthcare Solutions, for a purchase price of $405 million in cash, subject to certain customary post-closing adjustments. The purchase price was funded from Catamaran's existing cash balance.

9 Apr 2015

Particle Sciences receives patent for its surface arrayed therapeutics drug delivery platform

Particle Sciences, a leading drug delivery CDMO, has received a Notice of Allowance for composition and use of the technology incorporated into its SATx™ platform...

9 Apr 2015

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.

9 Apr 2015

Livongo Health secures $20 million in Series B funding

Livongo Health, a consumer digital health company that is empowering people with chronic diseases to live better, announced today that it has secured $20 million in Series B funding from investors including Kleiner Perkins Caufield & Byers (KPCB), DFJ and previous investor General Catalyst.

7 Apr 2015

Cerapedics closes $4 million term loan, raises additional $4 million in equity financing

Cerapedics, a privately-held orthobiologics company, today announced closing of a $4 million term loan from GE Capital, Healthcare Financial Services, bringing the total facility to $16.5 million. The company also announced it recently raised an additional $4 million in equity financing from inside investors.

7 Apr 2015

Nabriva Therapeutics completes $120 million Series B financing

Nabriva Therapeutics AG, a biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, today announced the successful completion of a $120 million Series B financing.

7 Apr 2015

DreaMed Diabetes and Medtronic enter strategic collaboration

DreaMed Diabetes, developer of diabetes treatment and management solutions, announced today that it had signed an exclusive worldwide development and license agreement with Medtronic, the world's premier medical technology and services company, for the development and marketing of products incorporating DreaMed’s MD-Logic Artificial Pancreas algorithm in Medtronic’s insulin pumps.

From Medtronic 7 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

High Throughput ChIP Sequencing

Chromatrap®, a business unit of Porvair Sciences, has announced a major product launch at the European Human Genetics Conference (Glasgow, UK) and the Festival of Genomics (Boston, USA) on the 6th June 2015 and 22nd-24th June 2015 respectively

From Chromatrap® - Porvair Sciences Ltd 6 Apr 2015